RetinalGenix Technologies Inc.

Equities

RTGN

US76133Y1055

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:47:02 2024-02-22 pm EST			5-day change	1st Jan Change
3.5 ^USD	+12.90%		-.--%	+13.27%

Apr. 01	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	RetinalGenix Technologies Inc. announced that it has received $4.65 million in funding	CI

RetinalGenix Technologies Inc. announced that it expects to receive $4.65 million in funding

January 22, 2024

RetinalGenix Technologies Inc. announced that it will receive $4,650,000 in funding on January 23, 2024. The company will issue convertible preferred stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
RetinalGenix Technologies Inc. announced that it has received $4.65 million in funding	Feb. 08	CI
RetinalGenix Technologies Inc. announced that it expects to receive $4.65 million in funding	Jan. 22	CI
RetinalGeniX?? Technologies Inc. Contracts with Medsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration	Dec. 26	CI
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Medical Advisory Board	Dec. 21	CI
RetinalGeniX Technologies Inc. Appoints Dessislava Boneva to its Board of Directors	Dec. 04	CI
RetinalGenix Technologies Inc. Appoints Virender Ahluwalia as Interim Chief Financial Officer	Dec. 01	CI
RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory Board	Nov. 28	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic Drugs	Nov. 09	CI
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device	Nov. 08	CI
RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration	23-10-30	CI
RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPS	23-08-28	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-18	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
RetinalGenix Technologies Inc. Appoints Vinay Mehindru to its Board of Directors	22-07-26	CI
RetinalGenix Technologies Inc. acquired DNA/GPS Inc. from Lawrence Perich for $14 million.	22-07-05	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI

Chart RetinalGenix Technologies Inc.

Duration

Period

More charts

Company Profile

RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The Company is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The Company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RETINALGENIX TECHNOLOGIES INC.	+13.27%	62.25M
MODERNA, INC.	+21.74%	46.4B
IQVIA HOLDINGS INC.	-0.97%	41.75B
LONZA GROUP AG	+47.07%	41.37B
CELLTRION, INC.	-3.52%	29.71B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.52B
MEDPACE HOLDINGS, INC.	+31.18%	12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.13B
BIO-TECHNE CORPORATION	+0.39%	12.18B

Other Biotechnology & Medical Research